Regeneron Pharmaceuticals, Inc. has secured US Food and Drug Administration approval for Pasatru, or garetosmab-grts, to reduce formation of new heterotopic ossification lesions and clinician-assessed disease flare-ups in adults with fibrodysplasia ossificans progressiva, giving patients with the ultra-rare genetic disorder a second FDA-approved treatment and validating a development programme that had previously encountered significant clinical setbacks. The approval is based on the randomized Phase 3 OPTIMA trial, where both evaluated Pasatru doses produced large reductions in newly formed bone lesions compared with placebo over 56 weeks.
Fibrodysplasia ossificans progressiva, or FOP, is caused by pathogenic variants involving ACVR1 and progressively turns muscles, tendons, ligaments and other connective tissues into bone. The resulting heterotopic ossification can progressively restrict movement, impair basic functions and ultimately contribute to severe disability and shortened survival. Regeneron estimates that about 900 people are diagnosed with FOP worldwide, illustrating both the extreme rarity of the condition and the difficulty of conducting controlled clinical studies large enough to support regulatory decisions.
Pasatru is administered by intravenous infusion once every four weeks. FDA recommends a starting dose of 10 mg/kg infused over 60 minutes, with the option to reduce treatment to 3 mg/kg every four weeks if the higher dose is not tolerated. That dosing recommendation is notable because both doses strongly suppressed new lesion formation in OPTIMA, but the higher dose generated a much larger reduction in clinician-assessed flare-ups.
What did OPTIMA show about new bone formation and FOP flare-ups?
OPTIMA randomized 63 adults with FOP to Pasatru at 10 mg/kg, Pasatru at 3 mg/kg or placebo every four weeks for 56 weeks. The study’s primary endpoint measured the number of new heterotopic ossification lesions detected through whole-body low-dose computed tomography, providing an anatomical measure of whether treatment was actually preventing formation of additional abnormal bone rather than relying entirely on symptoms or physician assessments.
Among 23 patients receiving the 10 mg/kg dose, investigators identified two new heterotopic ossification lesions at week 56, compared with 19 lesions among 21 placebo recipients. Regeneron characterized that as a 90% reduction. The 3 mg/kg group produced one new lesion among 19 patients, representing a 94% reduction from placebo. Both dose groups therefore met the primary endpoint with striking reductions in newly detectable abnormal bone formation.
The flare-up results were less symmetrical. Clinicians recorded nine disease flare-ups in the 10 mg/kg group over the 56-week period, compared with 53 in the 3 mg/kg group and 66 among placebo recipients. That translated into an 88% reduction relative to placebo for the higher dose but only a 15% reduction for the lower dose. Importantly, Regeneron also reported that differences in the proportion of patients experiencing patient-reported flare-ups were not statistically significant between Pasatru and placebo, preventing the physician-assessed flare-up result from being interpreted as an equally strong patient-reported symptom benefit.
This divergence helps explain why FDA selected 10 mg/kg as the recommended starting dose despite the 3 mg/kg group showing numerically fewer newly detected lesions. The primary imaging endpoint strongly favored both doses, but the clinician-assessed flare-up endpoint provides an additional reason to begin treatment at the higher exposure when patients can tolerate it.
The trial entered an extension after week 56, with 61 of the original participants continuing follow-up. Longer observation will matter because FOP progresses over years, while a one-year reduction in lesion formation does not establish how completely Pasatru can alter long-term mobility loss, cumulative heterotopic ossification or survival.
Why does blocking Activin A matter in fibrodysplasia ossificans progressiva?
FOP is usually associated with an activating mutation in ACVR1, a receptor involved in bone-forming signaling. Regeneron’s research helped establish that Activin A, which ordinarily does not trigger the same abnormal bone-growth response through the healthy receptor, can aberrantly activate mutant ACVR1 in FOP and drive heterotopic ossification.
Pasatru is a monoclonal antibody designed to neutralize Activin A, interrupting this disease-specific signaling pathway before it generates additional abnormal bone. FDA describes the medicine as blocking activation of the abnormal Activin A receptor type 1 pathway responsible for pathological bone formation.
The approach differs conceptually from treating the consequences of FOP after bone has already formed. Once mature heterotopic bone develops, surgical removal is generally problematic because tissue injury can itself provoke new ossification. Preventing additional lesions therefore addresses a central mechanism of progressive disability rather than attempting to reverse established skeletal restriction.
This biological targeting also makes the OPTIMA imaging data particularly meaningful. A large reduction in newly developing lesions is consistent with what would be expected if Activin A blockade is interfering with the molecular process responsible for disease progression.
At the same time, preventing new lesions is not equivalent to restoring movement already lost. Patients entering treatment with extensive established heterotopic bone may continue to experience substantial functional limitations even if further formation slows dramatically. That distinction will be important when clinicians and families assess expectations from treatment.
How did Regeneron move from a difficult Phase 2 programme to FDA approval?
Pasatru’s development was not a straightforward sequence of increasingly positive trials. The earlier Phase 2 LUMINA-1 study enrolled 44 adults and initially evaluated lesion activity as its primary efficacy endpoint. The trial did not meet that endpoint at the prespecified statistical threshold, with a reported P value of 0.0741. Five deaths also occurred during the open-label period, creating a serious safety issue that required further investigation even though investigators considered the deaths unlikely to be treatment-related and could not completely exclude causality.
Those findings contributed to a pause and redesign of the development programme rather than immediate progression along the originally envisioned path. Regeneron subsequently focused the pivotal OPTIMA trial on newly formed heterotopic ossification lesions measured using whole-body CT, producing a more direct and quantifiable structural endpoint.
The eventual Phase 3 result is therefore important not merely because it was positive, but because it answered a question that the earlier development programme had not resolved convincingly. The 90% and 94% reductions in new lesions gave FDA a markedly clearer efficacy signal while the placebo-controlled safety dataset allowed the agency to evaluate treatment risks in a more structured setting.
At 56 weeks in OPTIMA, serious treatment-emergent adverse events occurred in two patients receiving 10 mg/kg Pasatru, one patient receiving 3 mg/kg and two placebo recipients. Those numbers are small because the entire trial involved only 63 people, meaning uncommon adverse events cannot be reliably characterized from the pivotal population alone.
The regulatory outcome consequently illustrates a broader rare-disease development reality: a failed or ambiguous earlier endpoint does not necessarily invalidate the underlying biological target, but recovering from that result requires a trial capable of measuring the disease process more convincingly.
What safety issues will shape Pasatru use after approval?
Pasatru carries warnings for embryo-fetal toxicity, skin and soft-tissue infections that may require treatment or hospitalization, and epistaxis severe enough to require medical intervention. Patients who can become pregnant are advised to use effective contraception during therapy and for six months after the final dose.
The most common adverse reactions include nosebleeds, increased hair growth, abscesses and acne. Regeneron’s broader adverse-event listing also includes madarosis, oral ulcers, folliculitis, paronychia and rash. These effects are relevant in a treatment intended for repeated long-term infusion because tolerability will influence whether patients can remain on the recommended 10 mg/kg starting dose or need reduction to 3 mg/kg.
The monthly intravenous route introduces another practical consideration. Patients with severe FOP can have extensive mobility restrictions, and unnecessary trauma can itself be clinically problematic. Regeneron says Pasatru can be administered across appropriate care settings, including home infusion where medically suitable, which could reduce the burden of repeated travel for some patients.
Post-approval experience will be particularly useful in understanding safety in a larger population than could ever realistically be enrolled in an ultra-rare disease trial. With only hundreds of diagnosed patients globally, real-world pharmacovigilance could materially expand the evidence base over time.
Could pediatric development expand Pasatru beyond the initial adult indication?
The current FDA approval is restricted to adults, leaving a major development opportunity because FOP often begins in childhood and progressive heterotopic ossification can accumulate long before patients reach adulthood.
Regeneron plans to start the Phase 3 OPTIMA-2 programme in adolescents and children with FOP. ClinicalTrials.gov lists the study as a planned pediatric trial evaluating garetosmab in younger patients, with development extending over several years.
A successful pediatric programme could be particularly important because preventing new bone formation earlier in the disease course may theoretically preserve more function than beginning therapy after decades of accumulated ossification. That remains a clinical hypothesis rather than an established outcome, and pediatric development will need to address safety, growth and long-duration exposure carefully.
International expansion is also underway. Regeneron said a European regulatory application is under review and that filings in Japan and additional markets are planned.
Pasatru enters a field that is no longer entirely without approved treatment, since FDA approved Ipsen’s Sohonos in 2023. The availability of a second mechanistically distinct option is nevertheless significant in an ultra-rare disorder where treatment choices have historically been extremely limited.
The decisive Phase 3 finding is unusually concrete: adults receiving Pasatru developed only one or two new CT-detected heterotopic ossification lesions across the treatment groups compared with 19 lesions on placebo during 56 weeks. The harder long-term question is whether sustained suppression of that new bone formation preserves mobility, reduces cumulative disability and changes the natural history of FOP over many years.
